Iktos Stock

Iktos is a deep learning technology platform focused on new drug design and discovery.

Sign up today and learn more about Iktos Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Iktos Stock

Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.

Funding History

March 2023$15.5M


Chief AI Officer, Co-founder

Nicolas Do Huu

CEO & Co-Founder

Yann Gaston-Mathe

CSO & Co-Founder

Quentin Perron


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: